The visuo-cognitive and motor effect of amantadine in non-Caucasian patients with Parkinson's disease. A clinical and electrophysiological study

Journal of Neural Transmission

Volumn 109, Issue 1, 2002, Pages 41-51

  Bandini, F ^a,c,d,e   Pierantozzi, M ^b,c,d,e   Bodis Wollner, I ^d,e  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d Parkinson's Disease Foundation   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Amantadine; Non Caucasian patients; Parkinson's disease; Stimulus and event related visual evoked potential

Indexed keywords

AMANTADINE; LEVODOPA;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; CLINICAL STUDY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; EVENT RELATED POTENTIAL; EVOKED VISUAL RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MALE; MONOTHERAPY; NEGRO; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; STIMULUS RESPONSE; VISUAL DISCRIMINATION;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; AMANTADINE; ANTIPARKINSON AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITION; DRUG THERAPY, COMBINATION; ELECTROPHYSIOLOGY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; TREATMENT OUTCOME; VISUAL PERCEPTION;

EID: 0036170305     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s702-002-8235-5     Document Type: Article

References (35)

1. Visual discrimination and P300 are affected in parallel by cholinergic agents in the behaving monkey
2. Simultaneously evoked primary and cognitive visual evoked potentials distinguish younger and older patients with Parkinson's disease
3. Dopamine D2 receptor blockade alters the primary and cognitive components of visual evoked potentials in the monkey Macaca fascicularis
4. Exacerbation of Parkinson's disease following the withdrawal of amantadine
5. Glutamate and Parkinson's disease
6. The importance of physiology to visual evoked potentials
7. Transient benefit of amantadine in Parkinson's disease: The facts about the myth
8. Unified Parkinson's disease rating scale
9. 'Mini-mental state': A practical method for grading the cognitive state of patients for the clinician
10. Alterations in event related potentials of MPTP-treated monkeys
11. New lessons from old drugs: Amantadine and Parkinson's disease
12. Pharmacological pallidotomy with glutamate antagonists?
13. Parkinsonism: Onset, progression and mortality
14. Effects of 1-aminoadamantanes at the MK-801_binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study
15. The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissue
16. Progression of extrapyramidal signs in Parkinson's disease
17. Comparison of P100 and P300 cortical potentials in spatial frequency discrimination
18. Anticholinergic and membrane activities of amantadine in neuromuscular transmission
19. Effects of intravenous L-dopa on P300 and regional cerebral blood flow in parkinsonism
20. Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease
21. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: An electrophysiological investigation
22. Efficacy of memantine and NMDA receptor antagonist in the treatment of Parkinson's disease
23. New use for an old drug: Amantadine benefits levodopa-induced dyskinesia
24. Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK
25. Electrophysiological evidence for visuocognitive dysfunction in younger non-caucasian patients with Parkinson's disease
26. Amantadine influences cognitive processing in patients with multiple sclerosis
27. Excitatory amino acids and Parkinson's disease
28. Topographic mapping of long latency "cognitive" event-related potentials (P300): A double blind, placebo-controlled study with amantadine in mild dementia
29. Initiating therapy for Parkinson's disease
30. Dopaminergic influences on the P300 abnormality in Parkinson's disease
31. P300 variations in parkinsonian patients before and during dopaminergic monotherapy: A suggested dopamine component in P300
32. Evoked potentials, reaction time and cognitive performance in on and off phases of Parkinson's disease
33. More recent lessons from amantadine
34. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease
35. Amantadine for levodopa-induced dyskinesias. A 1-year follow-up study